Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The management of hyperthyroidism

J A Franklyn1

  • 1Department of Medicine, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, United Kingdom.

The New England Journal of Medicine
|June 16, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triiodothyronine regulates angiogenic growth factor and cytokine secretion by isolated human decidual cells in a cell-type specific and gestational age-dependent manner.

Human reproduction (Oxford, England)·2014
Same author

Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors.

The Journal of clinical endocrinology and metabolism·2013
Same author

Expression and function of thyroid hormone transporters in the microvillous plasma membrane of human term placental syncytiotrophoblast.

Endocrinology·2012
Same author

PTTG-binding factor (PBF) is a novel regulator of the thyroid hormone transporter MCT8.

Endocrinology·2012
Same author

The expression of thyroid hormone transporters in the human fetal cerebral cortex during early development and in N-Tera-2 neurodifferentiation.

The Journal of physiology·2011
Same author

Differential triiodothyronine responsiveness and transport by human cytotrophoblasts from normal and growth-restricted pregnancies.

The Journal of clinical endocrinology and metabolism·2010
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
Same journal

Ianalumab plus Eltrombopag in Immune Thrombocytopenia. Reply.

The New England journal of medicine·2026
Same journal

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients. Reply.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients.

The New England journal of medicine·2026
See all related articles

Current hyperthyroidism treatments are imperfect. Future therapies for Graves

Area of Science:

  • Endocrinology
  • Immunology
  • Pharmacology

Background:

  • Effective hyperthyroidism treatments exist but are not ideal.
  • Graves' disease requires therapies targeting the disease process, not just hormone synthesis.
  • Understanding Graves' disease pathogenesis is key to developing new treatments.

Purpose of the Study:

  • To review current hyperthyroidism treatments and identify needs for Graves' disease therapy.
  • To explore the potential of novel immunomodulatory treatments for Graves' disease.
  • To discuss the role of thyrotropin receptor and thyroid antigens in disease pathogenesis.

Main Methods:

  • Literature review of hyperthyroidism and Graves' disease treatments.
  • Analysis of recent advances in understanding thyroid autoimmunity.

Related Experiment Videos

  • Discussion of future therapeutic strategies based on immunomodulation.

    • Main Results:

    • No current treatment for Graves' disease perfectly modulates the disease process.
    • Cloning of the thyrotropin receptor and understanding immune interactions offer new therapeutic avenues.
    • Radioiodine therapy remains effective for hyperthyroidism control but often leads to hypothyroidism.

    Conclusions:

    • Targeted immunotherapies for specific thyroid antigens represent the future of Graves' disease treatment.
    • Broad immunosuppression is not a viable solution due to side effects.
    • Further research into thyroid autoimmunity is crucial for developing more effective and specific therapies.